Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease

a phase II study

Katarina Le Blanc, Francesco Frassoni, Lynne Ball, Franco Locatelli, Helene Roelofs, Ian Lewis, Edoardo Lanino, Berit Sundberg, Maria Ester Bernardo, Mats Remberger, Giorgio Dini, R. Maarten Egeler, Andrea Bacigalupo, Willem Fibbe, Olle Ringdén

Research output: Contribution to journalArticle

1821 Citations (Scopus)

Abstract

Background: Severe graft-versus-host disease (GVHD) is a life-threatening complication after allogeneic transplantation with haemopoietic stem cells. Mesenchymal stem cells modulate immune responses in vitro and in vivo. We aimed to assess whether mesenchymal stem cells could ameliorate GVHD after haemopoietic-stem-cell transplantation. Methods: Patients with steroid-resistant, severe, acute GVHD were treated with mesenchymal stem cells, derived with the European Group for Blood and Marrow Transplantation ex-vivo expansion procedure, in a multicentre, phase II experimental study. We recorded response, transplantation-related deaths, and other adverse events for up to 60 months' follow-up from infusion of the cells. Findings: Between October, 2001, and January, 2007, 55 patients were treated. The median dose of bone-marrow derived mesenchymal stem cells was 1·4×106 (min-max range 0·4-9×106) cells per kg bodyweight. 27 patients received one dose, 22 received two doses, and six three to five doses of cells obtained from HLA-identical sibling donors (n=5), haploidentical donors (n=18), and third-party HLA-mismatched donors (n=69). 30 patients had a complete response and nine showed improvement. No patients had side-effects during or immediately after infusions of mesenchymal stem cells. Response rate was not related to donor HLA-match. Three patients had recurrent malignant disease and one developed de-novo acute myeloid leukaemia of recipient origin. Complete responders had lower transplantation-related mortality 1 year after infusion than did patients with partial or no response (11 [37%] of 30 vs 18 [72%] of 25; p=0·002) and higher overall survival 2 years after haemopoietic-stem-cell transplantation (16 [53%] of 30 vs four [16%] of 25; p=0·018). Interpretation: Infusion of mesenchymal stem cells expanded in vitro, irrespective of the donor, might be an effective therapy for patients with steroid-resistant, acute GVHD. Funding: Swedish Cancer Society, Children's Cancer Foundation, Swedish Research Council, Cancer Society in Stockholm, Cancer and Allergy Foundation, Karolinska Institutet, Istituto Superiore di Sanità, European Union, Regione Lombardia, Fondazione CARIPLO, Associazione Italiana Ricerca contro il Cancro, Compagnia di San Paolo Torino, Progetto CARIGE Cellule Staminali, European Commission, Ministero dell'Università e della Ricerca Scientifica e Tecnologica, Ricerca Finalizzata Regione Liguria 2005 Assistenza Domiciliare, Dutch Programme for Tissue Engineering.

Original languageEnglish
Pages (from-to)1579-1586
Number of pages8
JournalLancet
Volume371
Issue number9624
DOIs
Publication statusPublished - 2008

Fingerprint

Graft vs Host Disease
Mesenchymal Stromal Cells
Steroids
Tissue Donors
Stem Cell Transplantation
Therapeutics
Neoplasms
Transplantation
Homologous Transplantation
European Union
Tissue Engineering
Acute Myeloid Leukemia
Siblings
Hypersensitivity
Stem Cells
Bone Marrow
Survival
Mortality
Research

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease : a phase II study. / Le Blanc, Katarina; Frassoni, Francesco; Ball, Lynne; Locatelli, Franco; Roelofs, Helene; Lewis, Ian; Lanino, Edoardo; Sundberg, Berit; Bernardo, Maria Ester; Remberger, Mats; Dini, Giorgio; Egeler, R. Maarten; Bacigalupo, Andrea; Fibbe, Willem; Ringdén, Olle.

In: Lancet, Vol. 371, No. 9624, 2008, p. 1579-1586.

Research output: Contribution to journalArticle

Le Blanc, K, Frassoni, F, Ball, L, Locatelli, F, Roelofs, H, Lewis, I, Lanino, E, Sundberg, B, Bernardo, ME, Remberger, M, Dini, G, Egeler, RM, Bacigalupo, A, Fibbe, W & Ringdén, O 2008, 'Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study', Lancet, vol. 371, no. 9624, pp. 1579-1586. https://doi.org/10.1016/S0140-6736(08)60690-X
Le Blanc, Katarina ; Frassoni, Francesco ; Ball, Lynne ; Locatelli, Franco ; Roelofs, Helene ; Lewis, Ian ; Lanino, Edoardo ; Sundberg, Berit ; Bernardo, Maria Ester ; Remberger, Mats ; Dini, Giorgio ; Egeler, R. Maarten ; Bacigalupo, Andrea ; Fibbe, Willem ; Ringdén, Olle. / Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease : a phase II study. In: Lancet. 2008 ; Vol. 371, No. 9624. pp. 1579-1586.
@article{f364cc4296ce4ad88005e33e4d03bb08,
title = "Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study",
abstract = "Background: Severe graft-versus-host disease (GVHD) is a life-threatening complication after allogeneic transplantation with haemopoietic stem cells. Mesenchymal stem cells modulate immune responses in vitro and in vivo. We aimed to assess whether mesenchymal stem cells could ameliorate GVHD after haemopoietic-stem-cell transplantation. Methods: Patients with steroid-resistant, severe, acute GVHD were treated with mesenchymal stem cells, derived with the European Group for Blood and Marrow Transplantation ex-vivo expansion procedure, in a multicentre, phase II experimental study. We recorded response, transplantation-related deaths, and other adverse events for up to 60 months' follow-up from infusion of the cells. Findings: Between October, 2001, and January, 2007, 55 patients were treated. The median dose of bone-marrow derived mesenchymal stem cells was 1·4×106 (min-max range 0·4-9×106) cells per kg bodyweight. 27 patients received one dose, 22 received two doses, and six three to five doses of cells obtained from HLA-identical sibling donors (n=5), haploidentical donors (n=18), and third-party HLA-mismatched donors (n=69). 30 patients had a complete response and nine showed improvement. No patients had side-effects during or immediately after infusions of mesenchymal stem cells. Response rate was not related to donor HLA-match. Three patients had recurrent malignant disease and one developed de-novo acute myeloid leukaemia of recipient origin. Complete responders had lower transplantation-related mortality 1 year after infusion than did patients with partial or no response (11 [37{\%}] of 30 vs 18 [72{\%}] of 25; p=0·002) and higher overall survival 2 years after haemopoietic-stem-cell transplantation (16 [53{\%}] of 30 vs four [16{\%}] of 25; p=0·018). Interpretation: Infusion of mesenchymal stem cells expanded in vitro, irrespective of the donor, might be an effective therapy for patients with steroid-resistant, acute GVHD. Funding: Swedish Cancer Society, Children's Cancer Foundation, Swedish Research Council, Cancer Society in Stockholm, Cancer and Allergy Foundation, Karolinska Institutet, Istituto Superiore di Sanit{\`a}, European Union, Regione Lombardia, Fondazione CARIPLO, Associazione Italiana Ricerca contro il Cancro, Compagnia di San Paolo Torino, Progetto CARIGE Cellule Staminali, European Commission, Ministero dell'Universit{\`a} e della Ricerca Scientifica e Tecnologica, Ricerca Finalizzata Regione Liguria 2005 Assistenza Domiciliare, Dutch Programme for Tissue Engineering.",
author = "{Le Blanc}, Katarina and Francesco Frassoni and Lynne Ball and Franco Locatelli and Helene Roelofs and Ian Lewis and Edoardo Lanino and Berit Sundberg and Bernardo, {Maria Ester} and Mats Remberger and Giorgio Dini and Egeler, {R. Maarten} and Andrea Bacigalupo and Willem Fibbe and Olle Ringd{\'e}n",
year = "2008",
doi = "10.1016/S0140-6736(08)60690-X",
language = "English",
volume = "371",
pages = "1579--1586",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Lancet Publishing Group",
number = "9624",

}

TY - JOUR

T1 - Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease

T2 - a phase II study

AU - Le Blanc, Katarina

AU - Frassoni, Francesco

AU - Ball, Lynne

AU - Locatelli, Franco

AU - Roelofs, Helene

AU - Lewis, Ian

AU - Lanino, Edoardo

AU - Sundberg, Berit

AU - Bernardo, Maria Ester

AU - Remberger, Mats

AU - Dini, Giorgio

AU - Egeler, R. Maarten

AU - Bacigalupo, Andrea

AU - Fibbe, Willem

AU - Ringdén, Olle

PY - 2008

Y1 - 2008

N2 - Background: Severe graft-versus-host disease (GVHD) is a life-threatening complication after allogeneic transplantation with haemopoietic stem cells. Mesenchymal stem cells modulate immune responses in vitro and in vivo. We aimed to assess whether mesenchymal stem cells could ameliorate GVHD after haemopoietic-stem-cell transplantation. Methods: Patients with steroid-resistant, severe, acute GVHD were treated with mesenchymal stem cells, derived with the European Group for Blood and Marrow Transplantation ex-vivo expansion procedure, in a multicentre, phase II experimental study. We recorded response, transplantation-related deaths, and other adverse events for up to 60 months' follow-up from infusion of the cells. Findings: Between October, 2001, and January, 2007, 55 patients were treated. The median dose of bone-marrow derived mesenchymal stem cells was 1·4×106 (min-max range 0·4-9×106) cells per kg bodyweight. 27 patients received one dose, 22 received two doses, and six three to five doses of cells obtained from HLA-identical sibling donors (n=5), haploidentical donors (n=18), and third-party HLA-mismatched donors (n=69). 30 patients had a complete response and nine showed improvement. No patients had side-effects during or immediately after infusions of mesenchymal stem cells. Response rate was not related to donor HLA-match. Three patients had recurrent malignant disease and one developed de-novo acute myeloid leukaemia of recipient origin. Complete responders had lower transplantation-related mortality 1 year after infusion than did patients with partial or no response (11 [37%] of 30 vs 18 [72%] of 25; p=0·002) and higher overall survival 2 years after haemopoietic-stem-cell transplantation (16 [53%] of 30 vs four [16%] of 25; p=0·018). Interpretation: Infusion of mesenchymal stem cells expanded in vitro, irrespective of the donor, might be an effective therapy for patients with steroid-resistant, acute GVHD. Funding: Swedish Cancer Society, Children's Cancer Foundation, Swedish Research Council, Cancer Society in Stockholm, Cancer and Allergy Foundation, Karolinska Institutet, Istituto Superiore di Sanità, European Union, Regione Lombardia, Fondazione CARIPLO, Associazione Italiana Ricerca contro il Cancro, Compagnia di San Paolo Torino, Progetto CARIGE Cellule Staminali, European Commission, Ministero dell'Università e della Ricerca Scientifica e Tecnologica, Ricerca Finalizzata Regione Liguria 2005 Assistenza Domiciliare, Dutch Programme for Tissue Engineering.

AB - Background: Severe graft-versus-host disease (GVHD) is a life-threatening complication after allogeneic transplantation with haemopoietic stem cells. Mesenchymal stem cells modulate immune responses in vitro and in vivo. We aimed to assess whether mesenchymal stem cells could ameliorate GVHD after haemopoietic-stem-cell transplantation. Methods: Patients with steroid-resistant, severe, acute GVHD were treated with mesenchymal stem cells, derived with the European Group for Blood and Marrow Transplantation ex-vivo expansion procedure, in a multicentre, phase II experimental study. We recorded response, transplantation-related deaths, and other adverse events for up to 60 months' follow-up from infusion of the cells. Findings: Between October, 2001, and January, 2007, 55 patients were treated. The median dose of bone-marrow derived mesenchymal stem cells was 1·4×106 (min-max range 0·4-9×106) cells per kg bodyweight. 27 patients received one dose, 22 received two doses, and six three to five doses of cells obtained from HLA-identical sibling donors (n=5), haploidentical donors (n=18), and third-party HLA-mismatched donors (n=69). 30 patients had a complete response and nine showed improvement. No patients had side-effects during or immediately after infusions of mesenchymal stem cells. Response rate was not related to donor HLA-match. Three patients had recurrent malignant disease and one developed de-novo acute myeloid leukaemia of recipient origin. Complete responders had lower transplantation-related mortality 1 year after infusion than did patients with partial or no response (11 [37%] of 30 vs 18 [72%] of 25; p=0·002) and higher overall survival 2 years after haemopoietic-stem-cell transplantation (16 [53%] of 30 vs four [16%] of 25; p=0·018). Interpretation: Infusion of mesenchymal stem cells expanded in vitro, irrespective of the donor, might be an effective therapy for patients with steroid-resistant, acute GVHD. Funding: Swedish Cancer Society, Children's Cancer Foundation, Swedish Research Council, Cancer Society in Stockholm, Cancer and Allergy Foundation, Karolinska Institutet, Istituto Superiore di Sanità, European Union, Regione Lombardia, Fondazione CARIPLO, Associazione Italiana Ricerca contro il Cancro, Compagnia di San Paolo Torino, Progetto CARIGE Cellule Staminali, European Commission, Ministero dell'Università e della Ricerca Scientifica e Tecnologica, Ricerca Finalizzata Regione Liguria 2005 Assistenza Domiciliare, Dutch Programme for Tissue Engineering.

UR - http://www.scopus.com/inward/record.url?scp=43049103438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43049103438&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(08)60690-X

DO - 10.1016/S0140-6736(08)60690-X

M3 - Article

VL - 371

SP - 1579

EP - 1586

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9624

ER -